We first consider a specific application for the aggregate utility approach that incorporates panel germline testing for ATM, BRCA1, BRCA2, CHEK2, and PALB2 as part of risk assessment for female breast cancer, for hypothetical screening of a woman without a previous breast cancer diagnosis or breast cancer family history. The gene discussed is CHEK2; the disease is breast carcinoma.